While this may also be true for SGLT2 inhibitors, based on the present findings, it is also possible that a difference from placebo was not detected because of the low statistical power due to the small number of episodes of incident AF and relatively short duration of follow‐up in DAPA‐HF. This evidence concerns the gene SLC5A2 and hydrops fetalis.